广济药业
(000952)
| 流通市值：19.37亿 | | | 总市值：19.70亿 |
| 流通股本：3.44亿 | | | 总股本：3.50亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 462,193,617.06 | 296,456,091.34 | 180,161,008.71 | 737,819,479.15 |
| 营业收入 | 462,193,617.06 | 296,456,091.34 | 180,161,008.71 | 737,819,479.15 |
| 二、营业总成本 | 628,443,566.8 | 404,570,942.57 | 239,269,664.37 | 862,656,234.17 |
| 营业成本 | 355,863,712.34 | 222,070,922.41 | 150,664,862.46 | 535,620,535.2 |
| 税金及附加 | 10,074,266.42 | 6,685,111.49 | 3,537,499.47 | 13,685,990.49 |
| 销售费用 | 28,388,827.8 | 19,405,311.19 | 10,435,235.88 | 38,638,723.43 |
| 管理费用 | 150,503,843.52 | 103,071,735.42 | 50,216,465.9 | 156,187,882.34 |
| 研发费用 | 44,704,949.95 | 28,423,514.81 | 16,095,943.13 | 74,751,639.39 |
| 财务费用 | 38,907,966.77 | 24,914,347.25 | 8,319,657.53 | 43,771,463.32 |
| 其中:利息费用 | 44,081,543.01 | 29,154,266.83 | 9,338,609.15 | 49,150,886.37 |
| 其中:利息收入 | 1,650,786.48 | 1,048,093.15 | 613,075.08 | 3,462,393.84 |
| 加:投资收益 | -3,643,763.21 | -2,924,601.73 | -855,481.24 | -10,023,610.91 |
| 资产处置收益 | - | - | 84,381.47 | 253,336.36 |
| 资产减值损失(新) | -14,763,673.28 | -12,608,697.7 | -741,260.77 | -14,264,476.34 |
| 信用减值损失(新) | 392,004.92 | -618,028.98 | -1,245,071.83 | -27,480.3 |
| 其他收益 | 13,747,602.28 | 8,208,509.29 | 5,679,908.26 | 7,845,753.78 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -170,517,779.03 | -116,057,670.35 | -56,186,179.77 | -141,053,232.43 |
| 加:营业外收入 | 1,106,544.29 | 1,060,091.37 | 1,073,404.48 | 1,198,141.88 |
| 减:营业外支出 | 1,588,135.66 | 25,675.88 | 91,667.27 | 811,454.65 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -170,999,370.4 | -115,023,254.86 | -55,204,442.56 | -140,666,545.2 |
| 减:所得税费用 | 1,457,811.36 | 540,487.2 | -535,008.06 | 11,747,676.19 |
| 六、净利润 | -172,457,181.76 | -115,563,742.06 | -54,669,434.5 | -152,414,221.39 |
| 持续经营净利润 | -172,457,181.76 | -115,563,742.06 | -54,669,434.5 | -152,414,221.39 |
| 归属于母公司股东的净利润 | -158,575,596.68 | -106,645,331.52 | -50,508,221.7 | -140,248,068.54 |
| 少数股东损益 | -13,881,585.08 | -8,918,410.54 | -4,161,212.8 | -12,166,152.85 |
| (一)基本每股收益 | -0.45 | -0.3 | -0.14 | -0.4 |
| (二)稀释每股收益 | -0.45 | -0.3 | -0.14 | -0.39 |
| 八、其他综合收益 | -1,591.39 | -4,500.42 | -4,537.19 | 13,971.3 |
| 归属于母公司股东的其他综合收益 | -1,591.39 | -4,500.42 | -4,537.19 | 13,971.3 |
| 九、综合收益总额 | -172,458,773.15 | -115,568,242.48 | -54,673,971.69 | -152,400,250.09 |
| 归属于母公司股东的综合收益总额 | -158,577,188.07 | -106,649,831.94 | -50,512,758.89 | -140,234,097.24 |
| 归属于少数股东的综合收益总额 | -13,881,585.08 | -8,918,410.54 | -4,161,212.8 | -12,166,152.85 |
| 公告日期 | 2024-10-31 | 2024-08-30 | 2024-04-26 | 2024-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |